Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Celadon Pharmaceuticals PLC, a UK-based pharmaceutical company, has successfully raised £2.1 million by issuing 2 million new shares at a premium. This funding, along with an extended £7 million credit facility, secures sufficient working capital for the next 12 months. The company has chosen not to pursue previously considered convertible loan note financing due to the successful equity issue and commencement of product supply to customers.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
